{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:27:08Z","timestamp":1784230028034,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K17111"],"award-info":[{"award-number":["21K17111"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["A18H04066"],"award-info":[{"award-number":["A18H04066"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjoms.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bjoms.2023.03.012","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T15:04:03Z","timestamp":1680275043000},"page":"320-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab"],"prefix":"10.1016","volume":"61","author":[{"given":"Hidetake","family":"Tachinami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Tomihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Imaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Kurohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Niiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Shimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Yanamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjoms.2023.03.012_b0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.12.035","article-title":"Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma","volume":"76","author":"Moy","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bjoms.2023.03.012_b0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.oraloncology.2018.07.005","article-title":"Clinical outcomes with therapies for previously treated recurrent\/metastatic head-and-neck squamous cell carcinoma (R\/M HNSCC): a systematic literature review","volume":"84","author":"Lala","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/lary.23264","article-title":"Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy?","volume":"122","author":"Spector","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1016\/j.bjoms.2023.03.012_b0020","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20640","article-title":"Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck","volume":"101","author":"Argiris","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bjoms.2023.03.012_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0030","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2023.03.012_b0035","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0040","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/hed.25737","article-title":"Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer","volume":"41","author":"Yasumatsu","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.bjoms.2023.03.012_b0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hed.24595","article-title":"Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck","volume":"39","author":"Chen","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.bjoms.2023.03.012_b0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1245\/s10434-018-6944-1","article-title":"The predictive value of pretreatment neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma","volume":"26","author":"Chen","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s10120-010-0554-3","article-title":"High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer","volume":"13","author":"Shimada","year":"2010","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bjoms.2023.03.012_b0060","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00268-011-0984-z","article-title":"Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma","volume":"35","author":"Garcea","year":"2011","journal-title":"World J Surg"},{"key":"10.1016\/j.bjoms.2023.03.012_b0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10147-012-0514-5","article-title":"Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to lymphocyte ratio and performance status","volume":"19","author":"Ohno","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/1754-9485.12305","article-title":"Neutrophil-to-lymphocyte ratio in head and neck cancer","volume":"59","author":"Haddad","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0075","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bjc.2016.23","article-title":"Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study","volume":"114","author":"Grenader","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bjoms.2023.03.012_b0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jgo.2019.06.013","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in older patients with head and neck cancer","volume":"11","author":"Ku","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0085","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193018","article-title":"The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer","volume":"13","author":"Kiriu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bjoms.2023.03.012_b0095","first-page":"335","article-title":"Baseline neutrophil-to-lymphocyte ratio and Glasgow prognostic score are associated with clinical outcome in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with nivolumab","volume":"75","author":"Chikuie","year":"2021","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.bjoms.2023.03.012_b0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.oraloncology.2017.05.002","article-title":"Turning the tide: clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck","volume":"70","author":"De Meulenaere","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/lio2.79","article-title":"The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer","volume":"2","author":"Heineman","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.bjoms.2023.03.012_b0115","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.bjoms.2023.03.012_b0120","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bjoms.2023.03.012_b0125","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","article-title":"Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells","volume":"67","author":"Nefedova","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bjoms.2023.03.012_b0130","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bjoms.2023.03.012_b0135","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","article-title":"Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bjoms.2023.03.012_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oraloncology.2019.02.014","article-title":"Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade","volume":"91","author":"Tachinami","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.oraloncology.2018.04.013","article-title":"Progression beyond nivolumab: stop or repeat? Dramatic responses with salvage chemotherapy","volume":"81","author":"Daste","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bjoms.2023.03.012_b0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1759-7714.12543","article-title":"Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy","volume":"9","author":"Ogawara","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.bjoms.2023.03.012_b0155","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"}],"container-title":["British Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435623000864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435623000864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:32:05Z","timestamp":1759419125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0266435623000864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0266435623000864"],"URL":"https:\/\/doi.org\/10.1016\/j.bjoms.2023.03.012","relation":{},"ISSN":["0266-4356"],"issn-type":[{"value":"0266-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab","name":"articletitle","label":"Article Title"},{"value":"British Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjoms.2023.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}